A COMPARATIVE STUDY OF C-PEPTIDE AND OTHER SURROGATE MARKERS OF INSULIN RESISTANCE IN GESTATIONAL DIABETES MELLITUS

Main Article Content

Dr. M. Lenin
Dr. J. Sivakumar
Dr. Kuzhandi velu
Dr. S. SelvaKumar
Dr. Ramesh Ramasammy

Keywords

Gestational diabetes mellitus, C-peptide, Insulin Resistance, HOMA-IR

Abstract

AIM: The current study aimed to investigate the relationship between C-peptide and other surrogate markers in patients with gestational diabetes mellitus in the Puducherry population.


Methodology: Five milliliters of venous blood (without anticoagulant) were drawn from pregnant women with and without GDM. The fasting glucose level was determined using the glucose oxidase method (GOD-POD), and the fasting lipid profile (total cholesterol, TAG-C, HDL-C, and LDL-C) was measured using an auto analyzer and the IFCC Approved method. Insulin resistance markers such as c-peptide and HOMA-IR were calculated. Insulin levels were calculated. Insulin was measured using chemiluminescence technology in a Roche auto analyzer (cobas e411).


Result: C-peptide had a strong relationship with insulin and HOMA-IR. In GDM, C-peptide has a higher sensitivity (88%) and specificity (89%). Conclusion: This study found a link between C-peptide levels and insulin levels in GDM patients in Puducherry, and C-peptide levels are predictive of GDM.


Conclusion: C-peptide can also be used to determine glycemic control status. C-peptide levels are used to predict gestational diabetes mellitus.

Abstract 163 | pdf Downloads 72

References

1. Virjee S, Robinson S, Johnston DG. Screening for diabetes in pregnancy. J R Soc Med. 2001 Oct;94(10):502–9.
2. Gupta K, Parmar M, Dubey S. Incidence of Gestational Diabetes Mellitus in Pregnant women from Rural Background Attending Antenatal Care Clinic. Int J Med Res Rev [Internet].2015Mar31[cited2017Oct10];3(02).Availablefrom:http://medresearch.in/inde x.php/IJMRR/article/view/229
3. Vani K. Alterations in lipid profile in gestational diabetes mellitus (GDM) and type 2 DM women during pregnancy. Int J Med Res Rev [Internet]. 2015 Sep 30 [cited 2017 May26];3(08). Available from: http://medresearch.in/index.php/IJMRR/article/view/351
4. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 2005 Mar 1;115(3):485–91.
5. Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab. 2015;19(1):160–4.
6. Cerf ME. Beta Cell Dysfunction and Insulin Resistance. Front Endocrinol [Internet]. 2013Mar27;4.Availablefrom: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608918
7. Chailurkit L, Jongjaroenprasert W, Chanprasertyothin S, Ongphiphadhanakul B. Insulin and C-peptide levels, pancreatic beta cell function, and insulin resistance across glucose tolerance status in Thais. J Clin Lab Anal. 2007;21(2):85–90.
8. Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action. Diabetes. 2010 Jul;59(7):1765–70.
9. Halliday HL, Reid MM, Hadden DR. C-peptide levels in transient neonatal diabetes. Diabet Med J Br Diabet Assoc. 1986 Jan;3(1):80–1
10. Viikari J, Rönnemaa T, Koskinen P. Glucagon-C-peptide test as a measure of insulin requirement in type 2 diabetes: evaluation of stopping insulin therapy in eleven patients. Ann Clin Res. 1987;19(3):178–82
11. Kampmann U, Madsen LR, Skajaa GO, Iversen DS, Moeller N, Ovesen P. Gestational diabetes: A clinical update. World J Diabetes. 2015 Jul 25;6(8):1065–72
12. Leighton E, Sainsbury CA, Jones GC. A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther. 2017 Jun;8(3):475–87.
13. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013 Jul;30(7):803–17.
14. Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, et al. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management.
15. Front Endocrinol [Internet]. 2017 Jan 24;8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256065/
16. Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes. 2010 May 15;1(2):36–47.
17. Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL. Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications. Curr Diabetes Rev. 2014 Jan;10(1):2–42.
18. Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations. Vasc Health Risk Manag. 2012;8:463–72.
19. Leibowitz G, Kaiser N, Cerasi E. β‐ Cell failure in type 2 diabetes. J Diabetes Investig. 2011 Apr 7;2(2):82–91.
20. Cernea S, Dobreanu M. Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Biochem Medica. 2013 Oct 15;23(3):266–80.
21. Marrif HI, Al-Sunousi SI. Pancreatic β Cell Mass Death. Front Pharmacol [Internet]. 2016Apr6;7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821858/
22. AMERICAN DIABETES ASSOCIATION. Diagnosis and Classification of Diabetes Mellitus. 31.
23. Bianchi C, Miccoli R, Trombetta M, Giorgino F, Frontoni S, Faloia E, et al. Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired β-Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study. J Clin Endocrinol Metab. 2013 May 1;98(5):2100
24. Radaelli T, Farrell KA, Huston-Presley L, Amini SB, Kirwan JP, McIntyre HD, et al. Estimates of Insulin Sensitivity Using Glucose and C-Peptide From the Hyperglycemia and Adverse Pregnancy Outcome Glucose Tolerance Test. Diabetes Care. 2010 Mar;33(3):490–4.
25. Shaat N, Ekelund M, Lernmark A, Ivarsson S, Ramelius A, Perfekt R, et al. Genotypic and phenotypic differences between Arabian and Scandinavian women with gestational diabetes mellitus. Diabetologia. 2004 Jun 1;47:878–84.
26. Ohkura T, Shiochi H, Fujioka Y, Sumi K, Yamamoto N, Matsuzawa K, et al. 20/(fasting C-peptide × fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol. 2013 Jan 22;12:21